UK watchdog says Cochlear's Oticon purchase can hurt competition

Cochlear

20/04/2023 07:42

April 20 (Reuters) - Britain's antitrust regulator said
on Thursday Australian hearing device maker Cochlear's  COH.AX 
acquisition of Danish rival Demant's  DEMANT.CO  hearing
implants business Oticon Medical could substantially reduce
competition.
    The Competition and Markets Authority (CMA) found a merger
between two of the biggest players in the UK's hearing implant
sector could lead to worse outcomes for the patients who rely on
these life-changing hearing implants and higher prices for the
state-owned National Health Service.
    
    
    
    
    


 (Reporting by Aby Jose Koilparambil in Bengaluru; Editing by
Rashmi Aich)
 ((abyjose.koilparambil@thomsonreuters.com; +919986528692;))